These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 989788)

  • 21. [Outcome of hemorrhage treatment in children with hemophilia A related to factor VIII inhibitor].
    Klukowska A; Zieleniewska B
    Acta Haematol Pol; 1994; 25(4):349-54. PubMed ID: 7847036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prothrombin complex concentrates. Use in treatment of hemophiliacs with factor VIII inhibitors.
    Yolken RH; Hilgartner MW
    Am J Dis Child; 1978 Mar; 132(3):291-3. PubMed ID: 629247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Editorial: Treatment of hemophilic children who have factor VIII inhibitors.
    Pearson HA
    J Pediatr; 1976 Feb; 88(2):367-8. PubMed ID: 1249715
    [No Abstract]   [Full Text] [Related]  

  • 25. Four-factor prothrombin complex concentrate for urgent reversal of vitamin K antagonists in patients with major bleeding.
    Quinlan DJ; Eikelboom JW; Weitz JI
    Circulation; 2013 Sep; 128(11):1179-81. PubMed ID: 23935012
    [No Abstract]   [Full Text] [Related]  

  • 26. Prothrombin complex concentrates: clinical use.
    Menache D
    Ann N Y Acad Sci; 1981; 370():747-56. PubMed ID: 6791551
    [No Abstract]   [Full Text] [Related]  

  • 27. PROPLEX vs. PROPLEX SX: a controlled double blind study of the effectiveness in treating acute hemarthroses in hemophilia A patients with inhibitors to factor VIII.
    Gomperts ED; Fannon RB; Lee ML; Kingdon HS; Kantrowitz JL; Addiego JE; Carney J; Corrigan JJ; Hathaway W; Hilgartner MW
    Thromb Res; 1986 Jun; 42(6):789-96. PubMed ID: 3726800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized study of factor VIII or prothrombin complex concentrate infusions in children with haemophilia and antibodies to factor VIII.
    Ekert H; Price DA; Lane JL; Dean FL
    Aust N Z J Med; 1979 Jun; 9(3):241-4. PubMed ID: 288389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Reflections on the use of PPSB fraction (Prothrombin-proconvertin-Stuart factor-antihemophilic factor B)].
    Malinvaud G
    Transfusion (Paris); 1966; 9(3):245-54. PubMed ID: 5969560
    [No Abstract]   [Full Text] [Related]  

  • 30. Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.
    Mahasandana C; Patharathienskul D; Suvatte V
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():106-12. PubMed ID: 7886549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of factor VIII inhibitors: evolution and current status.
    Bloom AL
    Haemostasis; 1992; 22(5):268-75. PubMed ID: 1478538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toxicity of factor IX concentrates in mice.
    Magner A; Aronson D
    Dev Biol Stand; 1979; 44():185-8. PubMed ID: 544292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-inhibitor Coagulant Complex (Autoplex) for treatment of factor VIII inhibitors in hemophilia.
    Abildgaard CF; Penner JA; Watson-Williams EJ
    Blood; 1980 Dec; 56(6):978-84. PubMed ID: 6777002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term results of the treatment of children with factor VIII inhibitors with prothrombin-complex concentrates.
    Ekert H; Smibert E; Exton J
    Med J Aust; 1987 Sep; 147(5):230-3. PubMed ID: 3118153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Letter: Concentrates of clotting-factor IX.
    Mannucci PM; Bader R; Ruggeri ZM
    Lancet; 1976 Jan; 1(7949):41. PubMed ID: 54544
    [No Abstract]   [Full Text] [Related]  

  • 36. Failure of factor VIII inhibitor bypassing activity (Feiba) to secure haemostasis in haemophilic patients with antibodies.
    Parry DH; Bloom AL
    J Clin Pathol; 1978 Nov; 31(11):1102-5. PubMed ID: 739057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of non-activated prothrombin concentrate in the management of haemophilia A with factor VIII antibodies.
    Price DA; d'Souza S; Ekert H
    Aust N Z J Med; 1977 Jun; 7(3):286-90. PubMed ID: 269689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of prothrombin complex concentrates in management of bleeding in hemophiliacs with inhibitors--benefits and limitations.
    Lusher JM
    Semin Hematol; 1994 Apr; 31(2 Suppl 4):49-52. PubMed ID: 7939776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Letter: Treatment of inhibitors to factor VIII with activated prothrombin concentrate.
    Sultan Y; Brouet JC; Debre P
    N Engl J Med; 1974 Nov; 291(20):1087. PubMed ID: 4414451
    [No Abstract]   [Full Text] [Related]  

  • 40. [Importance of PPSB fraction in the treatment of hemophilia A with antibodies against factor VIII].
    Hrubisková K
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1980; 107(4):672-82. PubMed ID: 6162735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.